FDA Proposes Blocking Three GLP-1 Drugs From 503B Bulk List
The FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying there is no clinical need for outsourcing facilities to compound these drugs from bulk substances. The agency invites comments by June 29, 2026, and will consider them before a final determination, citing patient safety and the integrity of the drug-approval process.
